25 XP   0   0   10

Phio Pharmaceuticals Corp
Buy, Hold or Sell?

Let's analyse Phio Pharmaceuticals Corp together

PenkeI guess you are interested in Phio Pharmaceuticals Corp. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Phio Pharmaceuticals Corp. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Phio Pharmaceuticals Corp

I send you an email if I find something interesting about Phio Pharmaceuticals Corp.

Quick analysis of Phio Pharmaceuticals Corp (30 sec.)










What can you expect buying and holding a share of Phio Pharmaceuticals Corp? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
10.0%

What is your share worth?

Current worth
$1.69
Expected worth in 1 year
$1.78
How sure are you?
27.5%

+ What do you gain per year?

Total Gains per Share
$0.09
Return On Investment
13.7%

For what price can you sell your share?

Current Price per Share
$0.67
Expected price per share
$0.5 - $1.15
How sure are you?
50%

1. Valuation of Phio Pharmaceuticals Corp (5 min.)




Live pricePrice per Share (EOD)

$0.67

Intrinsic Value Per Share

$-18.81 - $-9.28

Total Value Per Share

$-17.12 - $-7.59

2. Growth of Phio Pharmaceuticals Corp (5 min.)




Is Phio Pharmaceuticals Corp growing?

Current yearPrevious yearGrowGrow %
How rich?$7.7m$12.1m-$4m-49.4%

How much money is Phio Pharmaceuticals Corp making?

Current yearPrevious yearGrowGrow %
Making money-$2.2m-$3m$800k35.1%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Phio Pharmaceuticals Corp (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#700 / 1010

Most Revenue
#751 / 1010

Most Profit
#321 / 1010

Most Efficient
#188 / 1010

What can you expect buying and holding a share of Phio Pharmaceuticals Corp? (5 min.)

Welcome investor! Phio Pharmaceuticals Corp's management wants to use your money to grow the business. In return you get a share of Phio Pharmaceuticals Corp.

What can you expect buying and holding a share of Phio Pharmaceuticals Corp?

First you should know what it really means to hold a share of Phio Pharmaceuticals Corp. And how you can make/lose money.

Speculation

The Price per Share of Phio Pharmaceuticals Corp is $0.671. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Phio Pharmaceuticals Corp.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Phio Pharmaceuticals Corp, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.69. Based on the TTM, the Book Value Change Per Share is $0.02 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.66 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Phio Pharmaceuticals Corp.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.41-61.7%-0.50-74.3%-0.61-91.3%-0.57-84.5%-0.61-91.1%
Usd Book Value Change Per Share0.000.0%0.023.4%-0.66-98.9%-0.04-6.4%0.011.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.023.7%
Usd Total Gains Per Share0.000.0%0.023.4%-0.66-98.9%-0.04-6.4%0.034.9%
Usd Price Per Share0.68-1.46-1.82-1.58-1.37-
Price to Earnings Ratio-0.41--0.69--0.80--0.71--0.63-
Price-to-Total Gains Ratio3.07--2.50--0.94--2.86-
Price to Book Ratio0.40-0.78-1.01-0.60-1.52-
Price-to-Total Gains Ratio3.07--2.50--0.94--2.86-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.671
Number of shares1490
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.02-0.04
Usd Total Gains Per Share0.02-0.04
Gains per Quarter (1490 shares)34.12-64.03
Gains per Year (1490 shares)136.50-256.12
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101361260-256-266
202732620-512-522
304093980-769-778
405465340-1025-1034
506826700-1281-1290
608198060-1537-1546
709559420-1793-1802
80109210781-2050-2058
90122812141-2306-2314
100136513501-2562-2570

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.050.00.00.0%
Book Value Change Per Share2.01.01.050.0%2.09.01.016.7%5.014.01.025.0%10.029.01.025.0%13.036.01.026.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%1.00.019.05.0%4.00.036.010.0%4.00.046.08.0%
Total Gains per Share2.01.01.050.0%2.09.01.016.7%5.014.01.025.0%11.028.01.027.5%14.035.01.028.0%

Fundamentals of Phio Pharmaceuticals Corp

About Phio Pharmaceuticals Corp

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-12 15:06:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Phio Pharmaceuticals Corp.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Phio Pharmaceuticals Corp earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Phio Pharmaceuticals Corp to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Phio Pharmaceuticals Corp:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-4,866.6%+4,866.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--200.1%+200.1%
TTM--216.8%+216.8%
YOY--288.3%+288.3%
5Y--449.1%+449.1%
10Y-4,866.6%-605.5%-4,261.1%
1.1.2. Return on Assets

Shows how efficient Phio Pharmaceuticals Corp is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Phio Pharmaceuticals Corp to the Biotechnology industry mean.
  • -20.2% Return on Assets means that Phio Pharmaceuticals Corp generated $-0.20 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Phio Pharmaceuticals Corp:

  • The MRQ is -20.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -22.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-20.2%TTM-22.6%+2.3%
TTM-22.6%YOY-23.2%+0.6%
TTM-22.6%5Y-18.2%-4.4%
5Y-18.2%10Y-24.7%+6.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-20.2%-13.3%-6.9%
TTM-22.6%-12.8%-9.8%
YOY-23.2%-11.7%-11.5%
5Y-18.2%-13.9%-4.3%
10Y-24.7%-15.7%-9.0%
1.1.3. Return on Equity

Shows how efficient Phio Pharmaceuticals Corp is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Phio Pharmaceuticals Corp to the Biotechnology industry mean.
  • -24.5% Return on Equity means Phio Pharmaceuticals Corp generated $-0.25 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Phio Pharmaceuticals Corp:

  • The MRQ is -24.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -28.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-24.5%TTM-28.3%+3.8%
TTM-28.3%YOY-28.7%+0.3%
TTM-28.3%5Y-22.5%-5.8%
5Y-22.5%10Y-45.7%+23.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-24.5%-16.9%-7.6%
TTM-28.3%-16.1%-12.2%
YOY-28.7%-15.1%-13.6%
5Y-22.5%-19.3%-3.2%
10Y-45.7%-20.2%-25.5%

1.2. Operating Efficiency of Phio Pharmaceuticals Corp.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Phio Pharmaceuticals Corp is operating .

  • Measures how much profit Phio Pharmaceuticals Corp makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Phio Pharmaceuticals Corp to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Phio Pharmaceuticals Corp:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-4,892.0%+4,892.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--296.2%+296.2%
TTM--232.5%+232.5%
YOY--298.2%+298.2%
5Y--492.1%+492.1%
10Y-4,892.0%-632.4%-4,259.6%
1.2.2. Operating Ratio

Measures how efficient Phio Pharmaceuticals Corp is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Phio Pharmaceuticals Corp:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y94.635-94.635
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.231-3.231
TTM-3.310-3.310
YOY-3.890-3.890
5Y-5.739-5.739
10Y94.6357.876+86.759

1.3. Liquidity of Phio Pharmaceuticals Corp.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Phio Pharmaceuticals Corp is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.71 means the company has $5.71 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Phio Pharmaceuticals Corp:

  • The MRQ is 5.705. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.113. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.705TTM5.113+0.592
TTM5.113YOY6.079-0.966
TTM5.1135Y7.301-2.188
5Y7.30110Y6.275+1.026
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.7053.890+1.815
TTM5.1134.173+0.940
YOY6.0795.344+0.735
5Y7.3016.126+1.175
10Y6.2756.448-0.173
1.3.2. Quick Ratio

Measures if Phio Pharmaceuticals Corp is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Phio Pharmaceuticals Corp to the Biotechnology industry mean.
  • A Quick Ratio of 5.20 means the company can pay off $5.20 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Phio Pharmaceuticals Corp:

  • The MRQ is 5.196. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.384. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.196TTM3.384+1.812
TTM3.384YOY5.709-2.325
TTM3.3845Y6.678-3.294
5Y6.67810Y6.388+0.290
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.1963.514+1.682
TTM3.3843.998-0.614
YOY5.7095.380+0.329
5Y6.6786.105+0.573
10Y6.3886.404-0.016

1.4. Solvency of Phio Pharmaceuticals Corp.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Phio Pharmaceuticals Corp assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Phio Pharmaceuticals Corp to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.17 means that Phio Pharmaceuticals Corp assets are financed with 17.4% credit (debt) and the remaining percentage (100% - 17.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Phio Pharmaceuticals Corp:

  • The MRQ is 0.174. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.197. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.174TTM0.197-0.022
TTM0.197YOY0.175+0.022
TTM0.1975Y0.167+0.030
5Y0.16710Y0.268-0.101
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1740.339-0.165
TTM0.1970.336-0.139
YOY0.1750.271-0.096
5Y0.1670.366-0.199
10Y0.2680.389-0.121
1.4.2. Debt to Equity Ratio

Measures if Phio Pharmaceuticals Corp is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Phio Pharmaceuticals Corp to the Biotechnology industry mean.
  • A Debt to Equity ratio of 21.1% means that company has $0.21 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Phio Pharmaceuticals Corp:

  • The MRQ is 0.211. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.247. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.211TTM0.247-0.035
TTM0.247YOY0.216+0.031
TTM0.2475Y0.206+0.041
5Y0.20610Y0.546-0.341
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2110.388-0.177
TTM0.2470.402-0.155
YOY0.2160.335-0.119
5Y0.2060.426-0.220
10Y0.5460.461+0.085

2. Market Valuation of Phio Pharmaceuticals Corp

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Phio Pharmaceuticals Corp generates.

  • Above 15 is considered overpriced but always compare Phio Pharmaceuticals Corp to the Biotechnology industry mean.
  • A PE ratio of -0.41 means the investor is paying $-0.41 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Phio Pharmaceuticals Corp:

  • The EOD is -0.405. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.410. Based on the earnings, the company is expensive. -2
  • The TTM is -0.694. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.405MRQ-0.410+0.005
MRQ-0.410TTM-0.694+0.284
TTM-0.694YOY-0.797+0.103
TTM-0.6945Y-0.713+0.019
5Y-0.71310Y-0.630-0.084
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.405-2.264+1.859
MRQ-0.410-2.629+2.219
TTM-0.694-2.680+1.986
YOY-0.797-4.145+3.348
5Y-0.713-6.257+5.544
10Y-0.630-6.254+5.624
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Phio Pharmaceuticals Corp:

  • The EOD is -0.324. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.328. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.618. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.324MRQ-0.328+0.004
MRQ-0.328TTM-0.618+0.290
TTM-0.618YOY-0.759+0.141
TTM-0.6185Y-0.691+0.073
5Y-0.69110Y-0.701+0.010
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.324-2.973+2.649
MRQ-0.328-3.333+3.005
TTM-0.618-3.553+2.935
YOY-0.759-5.605+4.846
5Y-0.691-8.376+7.685
10Y-0.701-8.865+8.164
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Phio Pharmaceuticals Corp is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.40 means the investor is paying $0.40 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Phio Pharmaceuticals Corp:

  • The EOD is 0.397. Based on the equity, the company is cheap. +2
  • The MRQ is 0.402. Based on the equity, the company is cheap. +2
  • The TTM is 0.784. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.397MRQ0.402-0.005
MRQ0.402TTM0.784-0.381
TTM0.784YOY1.014-0.230
TTM0.7845Y0.601+0.183
5Y0.60110Y1.524-0.923
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.3971.896-1.499
MRQ0.4022.115-1.713
TTM0.7842.093-1.309
YOY1.0142.884-1.870
5Y0.6013.542-2.941
10Y1.5243.916-2.392
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Phio Pharmaceuticals Corp.

3.1. Institutions holding Phio Pharmaceuticals Corp

Institutions are holding 20.747% of the shares of Phio Pharmaceuticals Corp.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Sabby Management LLC3.41170.1724156039-713-0.4549
2023-09-30Vanguard Group Inc0.53302438000
2023-12-31Bridgeway Capital Management, LLC0.51350.00042348600
2023-12-31Renaissance Technologies Corp0.460402105613496.8453
2023-09-30Bank of Montreal0.437302000010000100
2023-09-30BMO Capital Markets Corp.0.437302000010000100
2023-09-30Geode Capital Management, LLC0.333015229152290
2023-09-30CAMBRIDGE Invest RESEARCH ADVISORS, INC.0.31120.00011423300
2023-09-30Cetera Investment Advisers0.23320.00011066600
2023-09-30Tower Research Capital LLC0.04380.0001200568251.5495
2023-09-30Citigroup Inc0.0209179170
2023-09-30Morgan Stanley - Brokerage Accounts0.0027012500
2023-09-30Wells Fargo & Co0.0003016545.4545
2023-09-30JPMorgan Chase & Co0.00010400
2023-12-31BlackRock Inc00100
2023-09-30Anson Funds Management LP000-22571-100
Total 6.73750.1731308157+14898+4.8%

3.2. Funds holding Phio Pharmaceuticals Corp

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.53302438000
2023-12-31Bridgeway Ultra-Small Company0.51350.02062348600
2024-02-29Fidelity Extended Market Index0.13990639900
2024-02-29Fidelity Nasdaq Composite Index0.06240285600
2024-02-29Fidelity Series Total Market Index0.0101046300
2023-12-31NT Ext Equity Mkt Idx Fd - L0.0085038800
2023-12-31Northern Trust Extended Eq Market Idx0.0085038800
2024-03-31State St US Extended Mkt Indx NL Cl C0.0049022500
2023-12-31SSgA U.S. Extended Market Index Class I0.0049022500
2024-02-29Spartan Extended Market Index Pool E0.001808100
2023-12-31NT US Market Cap Idx Fd - L0.001506800
2023-12-31Northern Trust Wilshire 50000.001506800
2023-12-31SSgA U.S. Total Market Index Strategy0.0014065-2-2.9851
2023-09-30BlackRock Extended Mkt Composite00100
2024-03-31BlackRock Extended Equity Market K00100
Total 1.29190.020659094-20.0%

3.3. Insider Transactions

Insiders are holding 0.756% of the shares of Phio Pharmaceuticals Corp.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-02-26Robert J BittermanBUY25000.91
2023-06-30Robert J BittermanBUY10002.88
2023-06-14Robert L FerraraBUY20003.1

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Phio Pharmaceuticals Corp compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.023-100%-0.6640%-0.0430%0.008-100%
Book Value Per Share--1.6901.781-5%2.661-36%3.164-47%2.269-26%
Current Ratio--5.7055.113+12%6.079-6%7.301-22%6.275-9%
Debt To Asset Ratio--0.1740.197-11%0.1750%0.167+5%0.268-35%
Debt To Equity Ratio--0.2110.247-14%0.216-2%0.206+3%0.546-61%
Dividend Per Share----0%-0%0.000-100%0.025-100%
Eps---0.414-0.498+20%-0.612+48%-0.567+37%-0.611+47%
Free Cash Flow Per Share---0.518-0.569+10%-0.629+21%-0.577+11%-0.507-2%
Free Cash Flow To Equity Per Share--0.007-0.031+526%-0.632+8860%-0.048+769%0.047-85%
Gross Profit Margin--1.0231.006+2%1.000+2%1.001+2%1.005+2%
Intrinsic Value_10Y_max---9.278--------
Intrinsic Value_10Y_min---18.809--------
Intrinsic Value_1Y_max---1.871--------
Intrinsic Value_1Y_min---2.414--------
Intrinsic Value_3Y_max---4.904--------
Intrinsic Value_3Y_min---6.838--------
Intrinsic Value_5Y_max---7.072--------
Intrinsic Value_5Y_min---10.773--------
Market Cap3068952.700-1%3110116.0006654733.500-53%8307439.995-63%7216955.573-57%6278306.556-50%
Net Profit Margin----0%-0%-0%-48.6660%
Operating Margin----0%-0%-0%-48.9200%
Operating Ratio----0%-0%-0%94.635-100%
Pb Ratio0.397-1%0.4020.784-49%1.014-60%0.601-33%1.524-74%
Pe Ratio-0.405+1%-0.410-0.694+69%-0.797+94%-0.713+74%-0.630+54%
Price Per Share0.671-1%0.6801.455-53%1.816-63%1.578-57%1.373-50%
Price To Free Cash Flow Ratio-0.324+1%-0.328-0.618+88%-0.759+131%-0.691+111%-0.701+114%
Quick Ratio--5.1963.384+54%5.709-9%6.678-22%6.388-19%
Return On Assets---0.202-0.226+12%-0.232+14%-0.182-10%-0.247+22%
Return On Equity---0.245-0.283+16%-0.287+17%-0.225-8%-0.457+86%
Total Gains Per Share---0.023-100%-0.6640%-0.0430%0.033-100%
Usd Book Value--7730000.0008144250.000-5%12169750.000-36%14468900.000-47%10376925.000-26%
Usd Book Value Change Per Share---0.023-100%-0.6640%-0.0430%0.008-100%
Usd Book Value Per Share--1.6901.781-5%2.661-36%3.164-47%2.269-26%
Usd Dividend Per Share----0%-0%0.000-100%0.025-100%
Usd Eps---0.414-0.498+20%-0.612+48%-0.567+37%-0.611+47%
Usd Free Cash Flow---2370000.000-2604000.000+10%-2874750.000+21%-2637950.000+11%-2317925.000-2%
Usd Free Cash Flow Per Share---0.518-0.569+10%-0.629+21%-0.577+11%-0.507-2%
Usd Free Cash Flow To Equity Per Share--0.007-0.031+526%-0.632+8860%-0.048+769%0.047-85%
Usd Market Cap3068952.700-1%3110116.0006654733.500-53%8307439.995-63%7216955.573-57%6278306.556-50%
Usd Price Per Share0.671-1%0.6801.455-53%1.816-63%1.578-57%1.373-50%
Usd Profit---1895000.000-2279750.000+20%-3079750.000+63%-2647600.000+40%-2515400.000+33%
Usd Revenue----0%-0%-0%11150.000-100%
Usd Total Gains Per Share---0.023-100%-0.6640%-0.0430%0.033-100%
 EOD+2 -5MRQTTM+17 -12YOY+15 -105Y+11 -1610Y+11 -22

4.2. Fundamental Score

Let's check the fundamental score of Phio Pharmaceuticals Corp based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.405
Price to Book Ratio (EOD)Between0-10.397
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than15.196
Current Ratio (MRQ)Greater than15.705
Debt to Asset Ratio (MRQ)Less than10.174
Debt to Equity Ratio (MRQ)Less than10.211
Return on Equity (MRQ)Greater than0.15-0.245
Return on Assets (MRQ)Greater than0.05-0.202
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Phio Pharmaceuticals Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.997
Ma 20Greater thanMa 500.685
Ma 50Greater thanMa 1000.798
Ma 100Greater thanMa 2000.777
OpenGreater thanClose0.708
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets9,364
Total Liabilities1,634
Total Stockholder Equity7,730
 As reported
Total Liabilities 1,634
Total Stockholder Equity+ 7,730
Total Assets = 9,364

Assets

Total Assets9,364
Total Current Assets9,322
Long-term Assets42
Total Current Assets
Cash And Cash Equivalents 8,490
Other Current Assets 832
Total Current Assets  (as reported)9,322
Total Current Assets  (calculated)9,322
+/-0
Long-term Assets
Property Plant Equipment 39
Long-term Assets Other 3
Long-term Assets  (as reported)42
Long-term Assets  (calculated)42
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities1,634
Long-term Liabilities0
Total Stockholder Equity7,730
Total Current Liabilities
Short-term Debt 35
Accounts payable 657
Other Current Liabilities 942
Total Current Liabilities  (as reported)1,634
Total Current Liabilities  (calculated)1,634
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Retained Earnings -139,206
Other Stockholders Equity 146,936
Total Stockholder Equity (as reported)7,730
Total Stockholder Equity (calculated)7,730
+/-0
Other
Cash and Short Term Investments 8,490
Common Stock Shares Outstanding 3,747
Liabilities and Stockholders Equity 9,364
Net Debt -8,455
Net Working Capital 7,688
Short Long Term Debt Total 35



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-31
> Total Assets 
0
0
0
1,694
1,327
8,019
6,712
5,592
19,972
17,996
16,211
14,938
12,459
12,550
10,901
9,189
7,169
14,953
12,697
11,159
8,174
6,521
4,901
13,397
10,512
8,391
6,033
4,098
3,090
6,031
3,809
15,322
13,678
12,108
10,079
8,039
14,305
20,211
18,239
15,739
33,856
31,657
27,943
25,170
22,162
20,144
15,791
12,814
9,707
12,296
9,539
9,364
9,364
9,3649,3649,53912,2969,70712,81415,79120,14422,16225,17027,94331,65733,85615,73918,23920,21114,3058,03910,07912,10813,67815,3223,8096,0313,0904,0986,0338,39110,51213,3974,9016,5218,17411,15912,69714,9537,1699,18910,90112,55012,45914,93816,21117,99619,9725,5926,7128,0191,3271,694000
   > Total Current Assets 
0
0
0
1,339
1,012
7,737
6,475
5,392
19,798
17,849
16,081
14,743
12,286
12,328
10,690
8,988
6,981
14,754
12,517
10,978
8,007
6,359
4,750
13,106
10,380
8,089
5,737
3,832
2,862
5,824
3,622
15,150
12,913
11,373
9,292
7,300
13,601
19,554
17,620
15,164
33,322
31,155
27,450
24,727
21,667
19,688
15,377
12,446
9,404
12,035
9,328
9,322
9,322
9,3229,3229,32812,0359,40412,44615,37719,68821,66724,72727,45031,15533,32215,16417,62019,55413,6017,3009,29211,37312,91315,1503,6225,8242,8623,8325,7378,08910,38013,1064,7506,3598,00710,97812,51714,7546,9818,98810,69012,32812,28614,74316,08117,84919,7985,3926,4757,7371,0121,339000
       Cash And Cash Equivalents 
0
0
0
503
357
7,575
6,278
5,127
19,643
8,587
6,847
11,390
9,010
11,911
5,130
8,496
6,580
5,986
4,035
5,117
4,192
3,832
2,379
12,906
10,205
7,702
5,416
3,581
2,606
5,315
3,240
14,879
12,746
10,816
8,709
6,934
13,284
18,864
16,868
14,244
32,695
29,425
26,529
24,057
20,459
18,020
14,484
11,781
9,035
11,307
8,407
8,490
8,490
8,4908,4908,40711,3079,03511,78114,48418,02020,45924,05726,52929,42532,69514,24416,86818,86413,2846,9348,70910,81612,74614,8793,2405,3152,6063,5815,4167,70210,20512,9062,3793,8324,1925,1174,0355,9866,5808,4965,13011,9119,01011,3906,8478,58719,6435,1276,2787,575357503000
       Short-term Investments 
0
0
0
0
0
0
53
53
53
9,000
9,000
3,000
3,000
50
5,000
50
50
8,000
8,000
5,500
3,500
2,000
2,000
50
50
50
50
50
50
50
50
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000050505050505050502,0002,0003,5005,5008,0008,00050505,000503,0003,0009,0009,000535353000000
       Net Receivables 
0
0
0
597
597
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000000000597597000
       Other Current Assets 
0
0
0
239
58
162
197
265
155
262
234
353
276
417
560
492
401
768
482
361
315
527
371
200
175
387
321
251
256
509
382
221
167
557
533
316
267
640
702
870
577
1,680
871
620
1,158
1,618
843
615
319
678
871
832
832
8328328716783196158431,6181,1586208711,68057787070264026731653355716722138250925625132138717520037152731536148276840149256041727635323426215526519716258239000
   > Long-term Assets 
0
0
0
355
315
282
237
200
174
147
130
195
173
222
211
201
188
199
180
181
167
162
151
291
132
302
296
266
228
207
187
172
765
735
787
739
704
657
619
575
534
502
493
443
495
456
414
368
303
261
211
42
42
4242211261303368414456495443493502534575619657704739787735765172187207228266296302132291151162167181180199188201211222173195130147174200237282315355000
       Property Plant Equipment 
0
0
0
355
315
282
235
198
172
147
130
177
155
204
193
183
170
181
162
163
149
135
124
114
105
275
269
248
228
207
187
172
747
717
769
721
686
639
601
557
516
484
466
416
468
429
390
344
297
255
208
39
39
3939208255297344390429468416466484516557601639686721769717747172187207228248269275105114124135149163162181170183193204155177130147172198235282315355000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
150
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000015000000000000000000000000
       Other Assets 
0
0
0
0
0
0
2
2
2
0
0
18
18
18
18
18
18
18
18
18
18
27
27
177
27
27
27
18
0
0
0
0
18
18
18
18
18
18
18
0
18
18
27
27
27
27
24
0
0
6
0
0
0
0006002427272727181801818181818181800001827272717727271818181818181818181800222000000
> Total Liabilities 
0
0
0
2,281
3,104
10,795
10,986
11,432
11,854
11,281
9,163
9,996
6,240
5,988
6,178
6,444
4,641
1,822
1,665
2,269
1,221
1,553
1,865
2,542
2,265
2,454
2,603
2,265
2,523
2,759
2,059
1,744
2,016
2,401
2,474
2,291
2,320
2,478
2,786
2,722
2,456
2,812
2,697
3,238
2,711
3,141
2,264
1,976
2,396
2,392
2,326
1,634
1,634
1,6341,6342,3262,3922,3961,9762,2643,1412,7113,2382,6972,8122,4562,7222,7862,4782,3202,2912,4742,4012,0161,7442,0592,7592,5232,2652,6032,4542,2652,5421,8651,5531,2212,2691,6651,8224,6416,4446,1785,9886,2409,9969,16311,28111,85411,43210,98610,7953,1042,281000
   > Total Current Liabilities 
0
0
0
1,776
2,099
1,366
1,411
1,679
1,958
1,510
1,342
2,076
1,390
1,053
1,156
1,334
1,556
1,822
1,665
2,269
1,221
1,553
1,865
2,542
2,265
2,454
2,603
2,265
2,523
2,759
2,059
1,744
1,516
1,936
2,036
1,880
1,937
1,893
2,230
2,196
2,191
2,578
2,495
3,068
2,573
3,037
2,194
1,804
2,396
2,392
2,326
1,634
1,634
1,6341,6342,3262,3922,3961,8042,1943,0372,5733,0682,4952,5782,1912,1962,2301,8931,9371,8802,0361,9361,5161,7442,0592,7592,5232,2652,6032,4542,2652,5421,8651,5531,2212,2691,6651,8221,5561,3341,1561,0531,3902,0761,3421,5101,9581,6791,4111,3662,0991,776000
       Short-term Debt 
0
0
0
29
18
11
9
5
2
0
0
0
0
0
0
997
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
92
102
104
107
109
111
113
116
118
120
112
125
127
130
132
135
138
104
70
0
35
35070104138135132130127125112120118116113111109107104102920000000000000000997000000259111829000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
92
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000009200000000000000000000000000000000
       Accounts payable 
0
0
0
387
747
277
155
416
366
358
177
163
277
293
137
285
459
635
222
1,163
281
297
457
917
672
741
702
511
521
542
491
550
721
736
856
809
685
481
742
728
615
348
322
283
329
1,148
543
779
902
641
173
657
657
6576571736419027795431,1483292833223486157287424816858098567367215504915425215117027416729174572972811,163222635459285137293277163177358366416155277747387000
       Other Current Liabilities 
0
0
0
544
537
610
877
767
1,126
913
1,018
1,795
1,024
682
958
5
1,097
1,187
1,443
1,106
940
1,256
1,408
1,625
1,593
1,713
1,901
1,754
2,002
2,217
1,568
1,194
795
1,200
1,180
27
1,252
1,412
1,488
104
1,458
2,110
2,061
2,660
2,117
1,759
1,519
890
1,356
1,647
2,083
0
942
94202,0831,6471,3568901,5191,7592,1172,6602,0612,1101,4581041,4881,4121,252271,1801,2007951,1941,5682,2172,0021,7541,9011,7131,5931,6251,4081,2569401,1061,4431,1871,09759586821,0241,7951,0189131,126767877610537544000
   > Long-term Liabilities 
0
0
0
505
1,005
9,429
9,575
9,753
9,896
9,771
7,821
7,920
4,850
4,935
5,022
5,110
3,085
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
500
465
438
411
383
585
556
526
265
234
202
170
138
104
70
172
1,040
0
0
0
0
00001,040172701041381702022342655265565853834114384655000000000000000003,0855,1105,0224,9354,8507,9207,8219,7719,8969,7539,5759,4291,005505000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
231
231
231
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000002312312310000000000000000000000000000000000000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
7,920
4,850
4,935
5,022
5,110
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000005,1105,0224,9354,8507,92000000000000
       Other Liabilities 
0
0
0
0
0
0
0
27
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000000270000000
> Total Stockholder Equity
0
0
0
-587
-1,777
-2,776
-4,274
-5,840
8,118
6,715
7,048
4,942
6,219
6,562
4,723
2,745
2,528
13,131
11,032
8,890
6,953
4,968
3,036
10,855
8,247
5,937
3,430
1,833
567
3,272
1,750
13,578
11,662
9,707
7,605
5,748
11,985
17,733
15,453
13,017
31,400
28,845
25,246
21,932
19,451
17,003
13,527
10,838
7,311
9,904
7,213
7,730
7,730
7,7307,7307,2139,9047,31110,83813,52717,00319,45121,93225,24628,84531,40013,01715,45317,73311,9855,7487,6059,70711,66213,5781,7503,2725671,8333,4305,9378,24710,8553,0364,9686,9538,89011,03213,1312,5282,7454,7236,5626,2194,9427,0486,7158,118-5,840-4,274-2,776-1,777-587000
   Common Stock
0
0
0
10
10
16
16
16
32
1
1
1
1
1
2
2
3
6
6
7
1
1
1
1
2
2
2
2
0
0
0
2
2
3
3
1
1
1
1
1
1
1
1
1
1
1
1
0
0
0
0
0
0
00000011111111111133220002222111176632211111321616161010000
   Retained Earnings Total Equity
0
0
0
0
0
0
0
0
0
0
0
38,082
40,366
-42,372
-44,578
-46,882
0
-51,993
-54,489
-57,105
-59,336
-61,548
-63,760
-66,099
-71,559
-74,073
-76,549
-78,551
-80,790
-82,691
-84,184
-85,911
-88,030
-90,065
-92,159
-94,819
-97,170
-98,842
-101,151
-103,613
-107,020
-109,707
0
0
0
0
0
0
0
0
0
0
0
00000000000-109,707-107,020-103,613-101,151-98,842-97,170-94,819-92,159-90,065-88,030-85,911-84,184-82,691-80,790-78,551-76,549-74,073-71,559-66,099-63,760-61,548-59,336-57,105-54,489-51,9930-46,882-44,578-42,37240,36638,08200000000000
   Accumulated Other Comprehensive Income 0000000000000000-1,048-1,04800-981-98100-900-90000-831-83100-778-778-12,697-14,953-702-70200-632-63200-9,896-5850-9,4240-646000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
40,969
41,964
44,586
47,452
48,047
0
65,118
65,515
65,988
66,288
66,515
66,795
73,428
79,806
80,010
79,979
80,384
81,357
85,963
85,934
99,487
99,690
99,769
99,761
100,566
109,154
116,574
116,603
116,629
138,419
138,551
0
0
0
0
0
0
0
0
0
0
0
00000000000138,551138,419116,629116,603116,574109,154100,56699,76199,76999,69099,48785,93485,96381,35780,38479,97980,01079,80673,42866,79566,51566,28865,98865,51565,118048,04747,45244,58641,96440,96900000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
4,326
4,416
11,009
1,580
2,160
39,640
30,458
40,602
41,601
41,964
44,586
47,452
48,749
52,331
65,118
65,515
55,607
66,288
66,515
66,795
74,259
79,804
80,008
79,977
81,284
81,357
85,963
85,934
100,468
99,690
99,769
99,761
101,614
109,154
116,574
116,603
116,629
138,419
138,551
138,694
138,831
138,992
139,075
139,175
139,216
129,586
132,139
134,985
0
146,936
146,9360134,985132,139129,586139,216139,175139,075138,992138,831138,694138,551138,419116,629116,603116,574109,154101,61499,76199,76999,690100,46885,93485,96381,35781,28479,97780,00879,80474,25966,79566,51566,28855,60765,51565,11852,33148,74947,45244,58641,96441,60140,60230,45839,6402,1601,58011,0094,4164,326000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-184
Gross Profit-184-184
 
Operating Income (+$)
Gross Profit-184
Operating Expense-10,514
Operating Income-10,698-10,698
 
Operating Expense (+$)
Research Development6,332
Selling General Administrative4,366
Selling And Marketing Expenses184
Operating Expense10,51410,882
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-10,698
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-10,826-10,570
EBIT - interestExpense = -10,698
-10,826
-10,826
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-10,698-10,826
Earnings Before Interest and Taxes (EBITDA)-10,514
 
After tax Income (+$)
Income Before Tax-10,826
Tax Provision-0
Net Income From Continuing Ops-11,662-10,826
Net Income-10,826
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses10,698
Total Other Income/Expenses Net-1280
 

Technical Analysis of Phio Pharmaceuticals Corp
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Phio Pharmaceuticals Corp. The general trend of Phio Pharmaceuticals Corp is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Phio Pharmaceuticals Corp's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Phio Pharmaceuticals Corp.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.7615 < 1.11 < 1.15.

The bearish price targets are: 0.5459 > 0.5.

Tweet this
Phio Pharmaceuticals Corp Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Phio Pharmaceuticals Corp. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Phio Pharmaceuticals Corp Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Phio Pharmaceuticals Corp. The current macd is -0.02954827.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Phio Pharmaceuticals Corp price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Phio Pharmaceuticals Corp. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Phio Pharmaceuticals Corp price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Phio Pharmaceuticals Corp Daily Moving Average Convergence/Divergence (MACD) ChartPhio Pharmaceuticals Corp Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Phio Pharmaceuticals Corp. The current adx is 23.49.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Phio Pharmaceuticals Corp shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Phio Pharmaceuticals Corp Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Phio Pharmaceuticals Corp. The current sar is 0.6101.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Phio Pharmaceuticals Corp Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Phio Pharmaceuticals Corp. The current rsi is 45.00. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Phio Pharmaceuticals Corp Daily Relative Strength Index (RSI) ChartPhio Pharmaceuticals Corp Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Phio Pharmaceuticals Corp. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Phio Pharmaceuticals Corp price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Phio Pharmaceuticals Corp Daily Stochastic Oscillator ChartPhio Pharmaceuticals Corp Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Phio Pharmaceuticals Corp. The current cci is -14.53595302.

Phio Pharmaceuticals Corp Daily Commodity Channel Index (CCI) ChartPhio Pharmaceuticals Corp Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Phio Pharmaceuticals Corp. The current cmo is -9.22505468.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Phio Pharmaceuticals Corp Daily Chande Momentum Oscillator (CMO) ChartPhio Pharmaceuticals Corp Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Phio Pharmaceuticals Corp. The current willr is -85.13027853.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Phio Pharmaceuticals Corp Daily Williams %R ChartPhio Pharmaceuticals Corp Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Phio Pharmaceuticals Corp. The current atr is 0.09388194.

Phio Pharmaceuticals Corp Daily Average True Range (ATR) ChartPhio Pharmaceuticals Corp Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Phio Pharmaceuticals Corp. The current obv is 109,142,060.

Phio Pharmaceuticals Corp Daily On-Balance Volume (OBV) ChartPhio Pharmaceuticals Corp Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Phio Pharmaceuticals Corp. The current mfi is 88.04.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Phio Pharmaceuticals Corp Daily Money Flow Index (MFI) ChartPhio Pharmaceuticals Corp Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Phio Pharmaceuticals Corp.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-05MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-06CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-29RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-30MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-31MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-21MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-22ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-01RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-12MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Phio Pharmaceuticals Corp Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Phio Pharmaceuticals Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.997
Ma 20Greater thanMa 500.685
Ma 50Greater thanMa 1000.798
Ma 100Greater thanMa 2000.777
OpenGreater thanClose0.708
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Phio Pharmaceuticals Corp with someone you think should read this too:
  • Are you bullish or bearish on Phio Pharmaceuticals Corp? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Phio Pharmaceuticals Corp? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Phio Pharmaceuticals Corp

I send you an email if I find something interesting about Phio Pharmaceuticals Corp.


Comments

How you think about this?

Leave a comment

Stay informed about Phio Pharmaceuticals Corp.

Receive notifications about Phio Pharmaceuticals Corp in your mailbox!